{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:03:49Z","timestamp":1781762629946,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cllc.2026.03.007","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:50:01Z","timestamp":1773939001000},"page":"108-116.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR\/ALK\/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8949-9614","authenticated-orcid":false,"given":"C.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arasaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Selbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Harden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-7912","authenticated-orcid":false,"given":"M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.cllc.2026.03.007_bib0001","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","article-title":"Global burden and trends of lung cancer incidence and mortality","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.007_bib0002","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.007_bib0003","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/tlcr-22-656","article-title":"Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer-a narrative review","volume":"12","author":"Chazan","year":"2023","journal-title":"Transl Lung Cancer Res"},{"issue":"29","key":"10.1016\/j.cllc.2026.03.007_bib0004","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.007_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.007_bib0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.007_bib0007","first-page":"e1","article-title":"Rebiopsy Feasibility and clinical impact on metastatic non-small-cell lung cancer With EGFR\/ALK\/ROS oncogenic driver progression after optimal targeted therapy: a multicenter real-world analysis","volume":"26","author":"Bronstein","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"9","key":"10.1016\/j.cllc.2026.03.007_bib0008","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.21037\/jtd-22-745","article-title":"EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience","volume":"14","author":"Dal Maso","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cllc.2026.03.007_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lungcan.2022.04.006","article-title":"Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications","volume":"168","author":"Scheffler","year":"2022","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.cllc.2026.03.007_bib0010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/1759-7714.13035","article-title":"Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure","volume":"10","author":"Zhou","year":"2019","journal-title":"Thorac Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2026.03.007_bib0011","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11523-025-01173-1","article-title":"Real-world outcomes of T790M mutation testing and sequential osimertinib in EGFR-positive advanced non-small cell lung cancer: a revisited strategy","volume":"20","author":"Yan","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.cllc.2026.03.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/809835","article-title":"Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments","volume":"2015","author":"Jekunen","year":"2015","journal-title":"J Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2026.03.007_bib0013","first-page":"181","article-title":"Attitudes of patients and physicians on repeat biopsies for lung cancer","volume":"2","author":"Chia","year":"2017","journal-title":"Expert Rev Qual Life Cancer Care"},{"issue":"4","key":"10.1016\/j.cllc.2026.03.007_bib0014","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.21873\/anticanres.15697","article-title":"Real-world afatinib outcomes in advanced non-small cell lung cancer harboring EGFR mutations","volume":"42","author":"Chen","year":"2022","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.007_bib0015","article-title":"The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M","volume":"11","author":"Huang","year":"2021","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.cllc.2026.03.007_bib0016","first-page":"3100","article-title":"T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study)","volume":"13","author":"Kuo","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"7","key":"10.1016\/j.cllc.2026.03.007_bib0017","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.21037\/tlcr-22-79","article-title":"Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22","volume":"11","author":"Jung","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2026.03.007_bib0018","unstructured":"Australian New Zealand Clinical Trials Registry, N.C.T.C., University of Sydney. Australasian Thoracic Cancers lOngitudinal cohoRt study and biobAnk. Identifier ACTRN126250000384932025, Sydney, Australia [cited 2025 January 1]; Available from: http:\/\/www.anzctr.org.au\/ACTRN12625000038493.aspx."},{"issue":"D1","key":"10.1016\/j.cllc.2026.03.007_bib0019","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.cllc.2026.03.007_bib0020","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/1759-7714.13143","article-title":"Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients","volume":"10","author":"Haratake","year":"2019","journal-title":"Thorac Cancer"},{"issue":"11","key":"10.1016\/j.cllc.2026.03.007_bib0021","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.21037\/tlcr-24-396","article-title":"Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study","volume":"13","author":"Kamali","year":"2024","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.007_bib0022","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jtcvs.2020.09.120","article-title":"Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma","volume":"163","author":"Matsuura","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.007_bib0023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.007_bib0024","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41392-025-02481-8","article-title":"A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib","volume":"10","author":"Shi","year":"2025","journal-title":"Signal TransductTarget Ther"},{"issue":"12","key":"10.1016\/j.cllc.2026.03.007_bib0025","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.cllc.2026.03.007_bib0026","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.cllc.2026.03.007_bib0027","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Sequist","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.007_bib0028","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cllc.2022.11.007","article-title":"Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC)","volume":"24","author":"Raez","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"10.1016\/j.cllc.2026.03.007_bib0029","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41416-022-01777-8","article-title":"Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?","volume":"127","author":"Bonanno","year":"2022","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2026.03.007_bib0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of <em>EGFR<\/em>second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2026.03.007_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.713530","article-title":"The resistance mechanisms and treatment strategies for ALK-rearranged non-small cell lung cancer","volume":"11","author":"Pan","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2026.03.007_bib0032","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/clinchem\/hvae008","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in ROS1 fusion-positive nonsmall cell lung cancer","volume":"70","author":"Zhao","year":"2024","journal-title":"Clin Chem"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:55:30Z","timestamp":1778025330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525730426000410"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.03.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping Real-world Rebiopsy Events to Treatment Trajectories in EGFR\/ALK\/ROS1-Driven Non-small-cell Lung Cancer: Insights from the AURORA Cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}